



(-1216HH

Patent Docket P1085R4-1A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Vanessa Hsei et al.

Serial No.: 09/234,182

Filed: 20 January 1999

For: ANTIBODY FRAGMENT-POLYMER

CONJUGATES AND HUMANIZED

ANTI-IL-8 MONOCLONAL

ANTIBODIES

Group Art Unit: 1644

Examiner: M. DiBrino

CERTIFICATE OF MAILING

Thereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

April 14, 2000

Yvonne Carter

TRANSMITTAL LETTER

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

- 1. Postcard
- 2. Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. (Copy)
- 3. Preliminary Amendment and Response to Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures
- 4. Certificate Re: Sequence Listing Response Under 37 CFR §1.821(f) and (g)
- 5. Sequence Listing (hard copy)
- 6. Sequence Listing in Computer Readable Form (CRF)

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: April 14, 2000

Richard B. Love

Reg. No. 34,659

1 DNA Way

So. San Francisco, CA 94080-4990

Phone: (650) 225-5530 Fax: (650) 952-9881

RECEIVED

Service of Contract of Contrac

UNITED STATE DEPARTMENT OF COMMERCE

Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

GENENTECH, INC.

MAR 2 7 2000

APPLICATION NO.

FILING DATE

FIRST NAMED INVENTOR

ATTORNEY DOCKET NO.

COPY

: 108441 | In

H同17 (11 (2))

COTTANTO O FUNDA LLNEMIFOU INC. I DNA MAG

न्त्रामान दृष्ट्य प्रारंश्य मध्यम देख अतम व



ART UNIT PAPER NUMBER

EXAMINER

17 2 2

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

22 APR 00

(10





ATES DEPARTMENT OF COMMERCE Patent and Trademark Office COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

SERIAL NUMBER FILING DATE FIRST NAMED APPLICANT ATTORNEY DOCKET NO.



EXAMINER PAPER NUMBER ART UNIT DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. See the attached copy of the marked-up "Raw Sequence Listing."

Any inquiry concerning this communication should be directed to Examiner Marianne DiBrino, Art Unit 1644, whose telephone number is 703-305-1987.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Marianne DiBrino, Ph.D.

March 19, 2000

SUPERVISORY PATENT EXAMINER GROUP 1800 7

Application No.: 09/34
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)


1. This application clearly falls to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.	S
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence". Usting as required by 37 C.F.R. 1.821(c).	9
3. A ∞py of the "Sequence Listing" in ∞mputer readable form has not been submitted as required b 37 C.F.R. 1.821(e).	У
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."	
5. The computer readable form that has been filed with this application has been found to be damage and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	⊬ď
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).	
7. Other:	
Applicant Must Provide:	
An interest substitute computer readable form (CRF) copy of the "Sequence Listing".	٠,
An Initial expositive paper copy of the "Sequence Listing", as well as an amendment directing its en into the specification.	(ry
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d). For questions regarding compliance to these requirements, please contact:	
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 For Patentin software help, call (703) 308-6856	
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE	

COPY FOR [] File [/ Applicant





RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following CRF diskette:

Application Serial Number:

09/234,182

Art Unit / Team No.:

1600

Date Processed by STIC:

1/29/99

THE ATTACHED PRINTOUT EXPLAINS THE ERRORS DETECTED.

PLEASE BE SURE TO FORWARD THIS INFORMATION TO THE APPLICANTS BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANTS ALONG WITH A NOTICE TO COMPLY or,
- 2) CALLING APPLICANTS AND FAXING THEM A COPY OF THE PRINTOUT WITH A NOTICE TO COMPLY

THIS WILL INSURE THAT THE NEXT SUBMISSION RECEIVED FROM THEM WILL BE ERROR FREE.

IF YOU HAVE ANY FURTHER QUESTIONS, PLEASE CALL:

MARK SPENCER 703-308-4212






re-run

PAGE: 1

RAW SEQUENCE LISTING PATENT APPLICATION US/09/234,182

DATE: 01/29/1999 TIME: 13:42:11





This Raw Listing contains the General Information Section and those Sequences containing ERRORS.

1 2		SEQUENCE LISTING	Does Not Comply Corrected Diskette Needed
3 4	(1)	General Information:	Corrected Diskette Mas
5 6 7 8 9 10	(i)	APPLICANT: Genentech, Inc., Hsei, Vanessa Koumenis, Iphigenia Leong, Steven R. Presta, Leonard G. Shahrokh, Zahra Zapata, Gerardo A.	
12 13 14	(ii)	TITLE OF INVENTION: ANTIBODY FRAGMENT-POLYMER OF HUMANIZED ANTI-IL-8 MONOCLO	
15 16	(iii)	NUMBER OF SEQUENCES: 72	
17 18 19 20 21 22 23	(iv)	CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc. (B) STREET: 1 DNA Way (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94080	
24 25 26 27 28 29 30	(v)	COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: WinPatin (Genentech)	
31 32 33 34 35	(vi)	CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: 20-Jan-1999 (C) CLASSIFICATION:	
36 37 38 39	(vii)	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/074330 (B) FILING DATE: 22-JAN-1998	
40 41 42 43	(vii)	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/094003 (B) FILING DATE: 24-JUL-1998	
44 45	(vii)	PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: 60/094013	



PAGE: 2

RAW SEQUENCE LISTING PATENT APPLICATION US/09/234,182

DATE: 01/29/1999 TIME: 13:42:11

INPUT SET: S30387.raw

46		(B) FILING DATE: 24-JUL-1998
47		
48	(vii)	PRIOR APPLICATION DATA:
49		(A) APPLICATION NUMBER: 60/075467
50		(B) FILING DATE: 20-FEB-1998
51		
52	(viii)	ATTORNEY/AGENT INFORMATION:
53		(A) NAME: Love, Richard B.
54		(B) REGISTRATION NUMBER: 34,659
55		(C) REFERENCE/DOCKET NUMBER: P1085R4-1A
56		
57	(ix)	TELECOMMUNICATION INFORMATION:
58		(A) TELEPHONE: 650/225-5530
59		(B) TELEFAX: 650/952-9881

ERRORED SEQUENCES FOLLOW:

	409	(2) INFORMATION FOR SEQ ID NO:22:
	410	44
	411	(i) SEQUENCE CHARACTERISTICS:
	412	(A) LENGTH: 21 base pairs (1)///A when wild with him
>	413	(B) TYPE DNA hucline and
	414	(C) STRANDEDNESS: Single
	415	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: DNA huclus and (DNA is only used with hew (C) STRANDEDNESS: Single (D) TOPOLOGY: Linear (Xi) SEQUENCE DESCRIPTION: SEO ID NO:22:
	416	, 0
	417	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:
	418	
	419	
	420	CCACTAGTAC GCAAGTTCAC G 21
	421	
	1151	(2) INFORMATION FOR SEQ ID NO:47:
	1152	
	1153	(i) SEQUENCE CHARACTERISTICS:
	1154	(A) LENGTH: 109 amino acids
>	1155	(B) TYPE (PRT) animo out
	1156	(D) TOPOLOGY: Linear
	1157	
	1158	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:
	1159	
	1160	Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val
	1161	1 5 10 15
	1162	
	1163	Gly Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Lys Thr Ile Ser
	1164	20 25 30
	1165	20
	1166	Lys Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys
	1167	35 40 45
	1168	.,
	1169	Leu Leu Ile Tyr Tyr Ser Gly Ser Thr Leu Glu Ser Gly Val Pro
	1100	hed hed the typ typ der dry ber this hed dra ber dry tar tro



1282

RAW SEQUENCE LISTING PATENT APPLICATION US/09/234,182

DATE: 01/29/1999 TIME: 13:42:11

				INPUT SET: S30387.raw	
1170		50	55	60	
1171					
1172	Ser Arg Phe Ser	Gly Ser Gly Ser	Gly Thr Asp Phe Th	r Leu Thr	
1173		65	70	75 ·	
1174					
1175	Ile Ser Ser Leu	Gln Pro Glu Asp	Phe Ala Thr Tyr Ty	r Cys Gln	
1176		80	85	90	
1177					
1178	Gln His Asn Glu	Tyr Pro Leu Thr	Phe Gly Gln Gly Th	r Lys Val	
1179		95	100	105	
1180					
1181	Glu Ile Lys Arg	1	1 2/	. I use every S	
1182	109-	me humb	a De avers o	in the second	,
1183				who works every 5.	el

1183	They rump	On
1250	(2) INFORMATION FOR SEQ ID NO:50:	· · · · · · · · · · · · · · · · · · ·
1251		
1252	(i) SEQUENCE CHARACTERISTICS:	
1253	(A) LENGTH: 116 amino acids	
1254	(B) TYPE: PRT	
1255	(D) TOPOLOGY: Linear	
1256		
1257	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:50:	
1258		
1259	Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly	
1260	1 5 10 15	
1261		
1262	Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Thr	
1263	20 25 30	
1264		
1265	Gly His Trp Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu	
1266	35 40 45	
1267		
1268	Glu Trp Val Gly Met Ile His Pro Ser Asp Ser Glu Thr Arg Tyr	
1269	50 55 60	
1270		
1271	Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser	
1272	65 70 75	
1273		
1274	Lys Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp	
1275	80 85 90	
1276		
1277	Thr Ala Val Tyr Tyr Cys Ala Ala Arg Gly Ile Tyr Phe Tyr Gly	
1278	95 100 105	
1279		
1280	Thr Thr Tyr Phe Asp Tyr Trp Gly Gln Gly Thr	
1281	110 115 116	

PAGE: 1



SEQUENCE VERIFICATION REPORT PATENT APPLICATION US/09/234,182

DATE: 01/29/1999

TIME: 13:42:12

INPUT SET: S30387.raw

Line	Error	Original Text
413	Wrong or Missing Sequence Type	(B) TYPE: DNA
1155	Wrong or Missing Sequence Type	(B) TYPE: PRT
1254	Wrong or Missing Sequence Type	(B) TYPE: PRT